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Abstract. The present study explored the usefulness of plasma amino acid 
concentrations in discriminating a subgroup of patients with transient acute poly- 
morphic psychoses characterized by psychosensory symptoms (APP+ patients). 
Levels of amino acids in the plasma of APPi- patients were compared with levels 
in psychiatric patients with other types of psychotic symptomatology and a 
healthy control group. Both the APP+ patients and patients with bipolar 
affective disorder had significantly lower plasma concentrations of serine com- 
pared with concentrations in the other groups studied. Since the plasma 
concentrations of taurine and methionine were also different in the APP+ 
patients, the ratio of taurine to the product of serine and methionine (the TSM 
ratio) was used in an attempt to increase the sensitivity in discriminating these 
patients. The TSM ratio in the APPi- patients was significantly higher than those 
in the other groups studied, except for the patients with bipolar affective disorder. 
It appears that the determination of serine and the TSM ratio in the plasma of 
psychotic patients may be a useful diagnostic validator in a group of patients with 
acute polymorphic psychoses. 
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In 1980, we observed a disturbed serine-glycine metabolism in a subgroup of patients 
with acute psychosis (Pepplinkhuizen et al., 1980). These transient, but often 
recurrent, psychotic episodes are characterized by a rich and varying mixture of 
symptomatology-intense emotional states ranging from overwhelming feelings of 
ecstasy to terrifying anxiety. Delusions and hallucinations are often minimal in these 
patients, who often suffer from sensory-perceptual anomalies of the type seen after 
LSD ingestion (e.g., distorted perceptions of colors, objects, space, body, and time). 
In Europe, this form of psychosis has been known as bouffee dklirante des 
degenerbes, degeneration psychosis, and cycloid psychosis, in particular, the ecstasy- 
anxiety subform. The ZCD-IO (World Health Organization, 1992) now classifies these 
psychoses as acute polymorphic psychotic disorders with or without symptoms of 
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schizophrenia (F23.0-F23.1). In DSM-III-R (American Psychiatric Association, 
1987), these psychotic disorders are categorized as psychotic disorders not elsewhere 
classified, with particular reference to the group of the schizoaffective (295.7) and 
schizophreniform disorders (295.40). 
Some APP patients report experiencing hallucinogenic drug-like sensory percep- 
tual distortions or “psychedelic experiences. ” Patients who fulfill the ZCD-IO criteria 
for an acute polymorphic psychosis, and who also report distorted sensory 
perceptions are designated as APP+, and those without perceptual disturbances as 
APP-. Discriminating this special group is warranted because APPi- patients 
typically do not respond to standard neuroleptic treatment (Bruinvels and 
Pepplinkhuizen, 1985), but they do benefit from treatment with the serotonin, 
receptor b!ocker ritanserin (Pepplinkhuizen, 1988). 
In an analogy with the transmethylation hypothesis of schizophrenia, we 
hypothesized that endogenous hallucinogenic substances might be responsible for 
the psychotic episodes of APP+ patients (Pepplinkhuizen et al., 1980). The 
following observations have linked a disturbed serine (ser) and related folate metabo- 
lism to the synthesis of putative hallucinogenic agents in the APPS patients: 
Oral loading with ser induced the reemergence of characteristic perceptual 
disturbances and psychedelic symptoms in most recovered APPf patients 
(Bruinvels et al., 1988; Pepplinkhuizen et al., 1980); the patients who experienced 
renewed symptoms in response to ser are termed the “ser positive” group. 
The plasma concentrations of ser and methionine (met) in APP+ patients were 
decreased, and the concentration of taurine ttau) was increased (Bruinvels and 
Pepplinkhuizen, 1984). 
The activities of the ser-metabolizing enzymes serine hydroxymethyltransferase 
and cystathionine fi-synthase were increased in eight patients in a pilot study 
(Fekkes et al., 1991). 
On the basis of the above findings. we decided to look at the “TSM ratio,” which is 
defined as the ratio of 100 times the tau concentration in plasma and the product of 
the plasma concentrations of ser and met. We measured concentrations of the amino 
acids ser, tau, and met in the plasma of several groups of psychotic patients. 
including our APP+ patients and a control group, and calculated the TSM ratios. It 
was hoped that the TSM ratio would prove to be a biochemical marker that could 
discriminate the APPf patients with greater sensitivity and specificity than the 
plasma ser concentration alone. If this proved to be the case, the TSM ratio might 
eventually replace the more invasive and burdensome ser loading test. 
Methods 
Subjects. We evaluated 22 healthy control subjects (group g; see Table I) who were 
randomly selected from among our hospital personnel (12 men and IO women; aged 21 to 48 
years) and 94 patients (47 men and 47 women; aged 19 to 53 years) who were admitted for an 
acute psychotic episode. With the exception of four bipolar patients, the patients had not yet 
been treated with antipsychotics during the month before the present admission. The final 
diagnostic subdivision of these 94 patients was as follows: (a) 18 acute psychotic patients 
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Table 1. Characteristics of psychotic patients and healthy control subjects 
Sex Challenge Psychopathological 
Diagnostic category (female/male) test’ reaction 
APP2, perceptual disturbances 
present (APP+; afb) 16/12 18 18 
APP, no perceptual disturbances 
present (APP-; c) 121 8 10 0 
Atypical psychosis (d) 91 3 3 0 
Bipolar affective disorder (e) 81 8 9 0 
Schizophrenia (f) 6112 6 0 
Healthy control subjects (g) 10112 15 0 
1, The challenge test was performed by giving the subjects an oral dose of serine (2 mmolikg body weight). 
2. APP = acute polymorphic psychosis. See Methods for explanation of groups a-g. 
suffering from APP+, all “ser positive” (Table I); (b) 10 APP+ patients who refused to 
undergo the ser-loading challenge; (c) 20 patients suffering from transient acute polymorphic 
psychosis without psychosensory symptoms (APP-); (d) 12 patients suffering from atypical 
psychoses according to DSM-III-R criteria (298.90); (e) 16 patients with bipolar affective 
disorder, of whom four were taking lithium medication; and (f) 18 schizophrenic patients. For 
an overview, see Table 1, which also shows the results of the ser challenge test performed in a 
number of patients and healthy subjects. 
Biochemical Determinations. Blood was drawn by venipuncture in heparinized tubes 
between 8 and 9 a.m. before breakfast. Blood sampling in the patients was done when 
psychotic symptoms were fully present and before the beginning of treatment with 
antipsychotic medication. The plasma was immediately separated by centrifugation for 5 
minutes at 1560 g,,, and stored at -30 “C. Within 3 months, 500 ~1 of plasma were 
deproteinized with 100~1 of 25% (w/v) sulfosalicylic acid containing a known amount of the 
internal standard norleucine. The amino acids in these samples were measured by ion- 
exchange chromatography on an LKB 4400 Amino Acid Analyzer with fluorescence detection 
(Bruinvels and Pepplinkhuizen, 1984). The ratio of the tau concentration and the product of 
the concentrations of ser and met was calculated and multiplied by 100 (TSM ratio). 
Statistics. Variables were tested for homogeneity of variances by means of Cochran’s C test. 
Multivariate analysis of variance (MANOVA) was used to test for differences in amino acid 
concentrations and TSM ratios across groups, followed by univariate analysis of variance 
(ANOVA) and Student-Newman-Keuls procedure for individual variables. In addition, 
Pearson’s correlation coefficients were calculated to investigate the relations between the 
amino acid concentrations and the TSM ratio. The significance level a was set at 0.05 
(two-tailed). 
Results 
All amino acid data were normally or log-normally distributed. Data for one bipolar 
patient were discarded, because both ser and met concentrations for this patient were 
extremely high. Table 2 lists the plasma levels of ser, tau, and met of several groups 
of patients and the control group. Group differences for the multivariate dimension 
were statistically significant (MANOVA: F = 4.05; # = 20,418; p < 0.001). 
Univariate tests showed that group differences existed for ser (F = 6.68; df = 5,109; 
p < O.OOOl), met (Fy4.11; df = 5,109;~ =0.0019), and the TSM ratio (F= 12.38; 
T
a
b
le
 2
. 
P
la
sm
a
 a
m
in
o
 a
ci
d
 l
e
ve
ls
 
a
n
d
 T
S
M
 
ra
ti
o
s 
o
f 
co
n
tr
o
l 
su
b
je
ct
s 
a
n
d
 p
sy
ch
o
ti
c 
p
a
ti
e
n
ts
 
S
e
ri
n
e
 
T
a
u
ri
n
e
 
M
e
th
io
n
in
e
 
T
S
M
 
D
ia
g
n
o
st
ic
 c
a
te
g
o
ry
 
n 
@
m
o
l/
l)
 
O
lm
o
lll
) 
~
m
o
l/
l)
 
ra
ti
o
 
A
P
P
+
 
(a
fb
) 
2
8
 
1
0
2
 i 
1
6
1
.
2
.
3
.
4
 
1
0
8
+
3
7
 
2
3
 +
 E
i3
 
4
.8
0
 +
 1
.4
9
1
.2
.3
.4
 
A
P
P
+
, 
se
r 
p
o
si
ti
v
e
 (a
) 
1
8
 
9
8
 +
 1
61
.2
,3
 
1
1
O
k3
8
 
2
2
 *
 
4
3
 
5
.0
7
 z
k 
1
.4
3
1
.2
,3
,4
 
A
P
P
+
, 
n
o
t 
lo
a
d
e
d
 (
b
) 
1
0
 
1
0
8
 k
 
1
5
 
1
0
5
+
3
9
 
2
3
 +
 5
3
 
4
.3
3
 +
 1
.5
7
’.
2
,s
 
A
P
P
- 
(c
) 
2
0
 
1
1
5
+
1
6
 
9
2
 +
 3
5
 
2
4
 +
 5
 
3
.3
9
 +
 1
.0
2
 
A
ty
p
ic
a
l p
sy
ch
o
se
s 
(d
) 
1
2
 
1
2
5
+
3
0
 
7
8
 i
 
2
9
 
2
6
 +
 4
 
2
.5
7
 +
 1
.2
0
 
B
ip
o
la
r 
a
ff
e
ct
iv
e
 (e
) 
1
5
 
1
0
1
 +
 1
6
1
~
3
 
9
4
 +
 2
9
 
2
3
 +
 3
3
 
4
.1
 1
 *
 
1
.3
0
1
,2
,3
 
S
ch
iz
o
p
h
re
n
ic
 p
a
ti
e
n
ts
 (f
) 
1
8
 
1
2
4
+
2
6
 
9
1
 +
 3
0
 
2
8
 +
 5
4
 
2
.7
7
 +
 0
.9
9
 
C
o
n
tr
o
l s
u
b
je
ct
s 
(g
) 
2
2
 
1
2
5
 +
 1
6
 
9
0
+
1
6
 
2
6
 +
 4
 
2
.9
0
 *
 
0
.5
4
 
N
o
te
. A
ll 
re
su
lt
s 
a
re
 e
x
p
re
ss
e
d
 a
s 
m
e
a
n
s 
+
 1
 S
D
. 
S
e
e
 M
e
th
o
d
s 
fo
r 
e
x
p
la
n
a
ti
o
n
 o
f 
g
ro
u
p
s a
-g
. A
P
P
+
 =
 a
cu
te
 p
o
ly
m
o
rp
h
ic
 p
sy
ch
o
si
s w
it
h
 p
sy
ch
o
se
n
so
ry
 sy
m
p
to
m
s,
 
A
P
P
- 
=
 a
cu
te
 p
o
ly
m
o
rp
h
ic
 
p
sy
ch
o
si
s w
it
h
o
u
t p
sy
ch
o
se
n
so
ry
 
sy
m
p
to
m
s.
 
T
S
M
 r
a
ti
o
 =
 th
e
 ra
ti
o
 o
f t
a
u
ri
n
e
 to
 th
e
 p
ro
d
u
ct
 o
f s
e
ri
n
e
 a
n
d
 m
e
th
io
n
in
e
. 
1. 
p 
< 
0
.0
5
 v
s.
 c
o
n
tr
o
l su
b
je
ct
s.
 
2
. p
 
< 
0.
05
 
vs
. 
a
ty
p
ic
a
l ps
y
ch
o
sl
s.
 
3
. p
 <
 0
.0
5
 v
s.
 s
ch
iz
o
p
h
re
n
ic
 p
a
ti
e
n
ts
. 
4
. p
 
< 
0
.0
5
 v
s.
 A
P
P
- 
(o
n
e
-w
a
y
 a
n
a
ly
si
s 
o
f 
v
a
ri
a
n
ce
) 
15 
df = 5,109;~ < O.OOOl), but not for tau (F= 1.88; df = 5,109;~ = 0.103). With the 
Student-Newman-Keuls procedure for individual variables, it was found that the 
APP+ patients (groups a + b) showed significantly lower plasma ser levels 
compared with control subjects (group g; see Fig. I), APP- patients (group c), 
schizophrenic patients (group f), and patients with atypical psychoses (group d). The 
plasma ser concentration (mean I!I 1 SD) of the 18 ser-positive patients (group a; 
98 YE 16pM) was slightly lower than the ser level in the plasma of the APPf patients 
who refused to participate in the loading experiment (group b; 108 + 15 ,uM). No 
differences were found between APP-t patients and patients with bipolar affective 
disorder (group e). The plasma level of ser (101 + 16pM) in the bipolar patients was 
significantly lower than in the control subjects, the schizophrenic patients, and the 
atypical psychotic patients. 
The plasma levels of tau showed no significant differences between groups, 
although the tau concentration in the APPS patients was slightly higher than in the 
other groups studied. The plasma levels of met in both APP+ and APP- patients 
did not differ from the values in the control group or in the bipolar and atypical 
Fig. 1. Scatter plots of serine concentrations (in ~mol/l) and TSM ratios in 
blood plasma of 28 APP+ patients and 22 healthy control subjects 
150- 
130- 
llO- 
go- 
controls APP+ patients 
I 7 
TSM-Ratio 
0 
Oc.O 
controls APP+ patients 
The error bars indicate the mean and SD. TSM ratio = the ratio of taurine to the product of serine and methionine. 
APP+ = acute polymorphic psychosis with psychosensory symptoms. 
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psychosis patients. However, the met concentration in the plasma of the schizo- 
phrenic patients was significantly higher than in the plasma of APP+ patients, 
APP- patients, and bipolar affective patients. 
Table 2 also displays the TSM ratios. The ratio in the ser-positive patient group 
was significantly higher than the ratio in the control group (Fig. I) or in the other 
groups of psychiatric patients except for the bipolar patients. The same was true for 
all APPf patients. The TSM ratio in the bipolar patient group was significantly 
higher than in the atypical psychotic patients, the schizophrenic patients, or the 
control subjects. No difference in TSM ratio was found between the control subjects 
and the schizophrenic, atypical psychotic, or APP- patients. 
The plasma tau concentration was positively correlated with the TSM ratio in 
every single patient group studied (r > 0.54,~ < 0.02) but not in the control subjects 
(r = 0.25, p = 0.225). Another interesting finding was that the plasma tau level 
correlated positively with the plasma met concentration only in the APP patients, 
irrespective of the presence of psychedelic symptoms (r > 0.53, p < 0.003). 
Discussion 
The plasma levels of ser and met in the group of healthy control subjects in this study 
are in agreement with those reported in other studies (Bjerkenstedt et al., 1985; 
Waziri and Mott, 1986; Rao et al., 1990). However, the plasma concentration of tau 
was higher than in most other studies. This is due to the short centrifugation time 
(5 minutes) and the relatively low centrifugal speed (1560g) that we used for the 
plasma preparation. This yields plasma containing high amounts of blood platelets, 
which are known to be rich in the amino acid tau. 
As in our previous studies (Bruinvels and Pepplinkhuizen, 1984, 1985), we found 
significantly lower plasma ser concentrations in APPS patients than in control 
subjects. The plasma tau concentration in these patients was - as in an earlier study 
(Bruinvels and Pepplinkhuizen, 1984) - slightly elevated, although not to a statistic- 
ally significant degree. The bipolar affective patients also had decreased plasma ser 
concentrations. This is in contradiction to an earlier study (Bruinvels and 
Pepplinkhuizen, 1984), although that study included only three bipolar patients. 
Psychopharmacologic treatment was not the cause of these low plasma ser levels, 
since exclusion of the data of the medicated patients resulted in comparable (102 + 
17 @4) plasma ser concentrations. 
The TSM ratio discriminated the APPI- patients with greater sensitivity 
(F = 12.38) than did the plasma ser concentration alone (F = 6.68). However, the 
specificity was not better, because the TSM ratio in the bipolar affective patients was 
only slightly lower (4.11 t 1.30) than in the APP+ patients (4.80 f 1.49). 
Plasma ser levels did not differ among control subjects, patients suffering from 
atypical psychoses, and schizophrenic patients. This finding is in agreement with the 
results reported by Perry and Hansen (1985) Bjerkenstedt et al. (1985) and Rao et 
al. (1990) for schizophrenic patients. Although the plasma ser levels in the normal 
control subjects (125 ,YM) were comparable to those published by Waziri and Mott 
(1986, 117 PM), the very high ser concentration of 205 ,CIM in the plasma of psychotic 
patients reported by these investigators was not found in our patients. The plasma 
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ser concentration of 133 ,crM in the schizophrenic patients studied by Macciardi et al. 
(1990) was comparable to the value that we found (123 ph4). However, the plasma 
ser level in the control group studied by Macciardi et al. was lower (109 ,vUM) than 
that in our control group (125 HUM). The possibility of a drug effect on plasma ser 
concentrations can be ruled out, as omission of the data of medicated patients did 
not result in higher ser levels. This is in accordance with the results of Rao et al. 
(1990), who reported that medication had no effect on serum ser levels in 
schizophrenic patients. 
Concerning the plasma met concentrations, we found no differences between 
schizophrenic patients and control subjects. This is in line with the results reported 
by Rao et al. (1990) but in contradiction to those reported by Bjerkenstedt et al. 
(1985) and Macciardi et al. (1990), who both found increased levels of met in the 
plasma of schizophrenic patients. 
The explanation for the discrepancies between the plasma ser concentrations in 
schizophrenic patients reported by different investigators is unclear. Possibly, a 
combination of several slightly differing factors among the studies (e.g., techniques 
of blood withdrawal, processing, storage and amino acid analysis, dietary intake, 
gender, diagnosis, and medication) accounts for these discrepancies. The major 
finding of this study is that a decreased plasma ser concentration and an increased 
TSM ratio both are at least state markers for the subgroup of episodic psychotic 
(APPf) patients (Fig. 1). However, these markers cannot differentiate between 
APP+ patients and bipolar affective patients. An investigation of the TSM ratio as a 
trait marker is in progress. 
In conclusion, a suggestive diagnosis can be based on the presence of an episodic 
acute psychosis with sensory perceptual distortions and psychedelic symptoms, a 
kaleidoscopic polymorphic clinical picture, a low plasma serine concentration, and a 
high TSM ratio. However, confirmation of this diagnosis requires the development 
of characteristic symptoms after oral challenge with serine. 
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